586 related articles for article (PubMed ID: 31407412)
21. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
[TBL] [Abstract][Full Text] [Related]
22. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
Ronquillo JG; Zuckerman DM
Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
[TBL] [Abstract][Full Text] [Related]
23. Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
Li W; Wertheimer A
Innov Pharm; 2023; 14(1):. PubMed ID: 38035313
[No Abstract] [Full Text] [Related]
24. How drugs are developed and approved by the FDA: current process and future directions.
Ciociola AA; Cohen LB; Kulkarni P;
Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
[TBL] [Abstract][Full Text] [Related]
25. US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information.
Ridge S; Guinn D; Pfuma Fletcher E; Zineh I; Madabushi R; Ramamoorthy A
J Clin Pharmacol; 2023 Jun; 63(6):695-703. PubMed ID: 36731882
[TBL] [Abstract][Full Text] [Related]
26. The drug approval process and the information it provides.
Myers A; Moore SR
Drug Intell Clin Pharm; 1987 Oct; 21(10):821-6. PubMed ID: 3322757
[TBL] [Abstract][Full Text] [Related]
27. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
[TBL] [Abstract][Full Text] [Related]
28. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
29. FDA recognition of consensus standards in the premarket notification program.
Marlowe DE; Phillips PJ
Biomed Instrum Technol; 1998; 32(3):301-4. PubMed ID: 9619259
[TBL] [Abstract][Full Text] [Related]
30. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
[TBL] [Abstract][Full Text] [Related]
32. Renovations Needed: the FDA's Floor/Ceiling Framework, Preemption, and the Opioid Epidemic.
Abrams MR
Mich Law Rev; 2018 Oct; 117(1):143-71. PubMed ID: 30300989
[TBL] [Abstract][Full Text] [Related]
33. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
34. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
35. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
Abraham J; Davis C
Soc Sci Med; 2005 Sep; 61(5):881-92. PubMed ID: 15955393
[TBL] [Abstract][Full Text] [Related]
36. The US Opioid Crisis: Current Federal and State Legal Issues.
Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
[TBL] [Abstract][Full Text] [Related]
37. US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.
Eadie A; MacGregor A; Wallach J; Ross J; Herder M
BMJ Evid Based Med; 2023 Jun; 28(3):151-156. PubMed ID: 36944478
[TBL] [Abstract][Full Text] [Related]
38. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
39. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.
Zhang AD; Schwartz JL; Ross JS
Milbank Q; 2019 Sep; 97(3):796-819. PubMed ID: 31304643
[TBL] [Abstract][Full Text] [Related]
40. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
